HADD SCIENCE

🧬 HADD Science × Corestem Chemon join hands to co-develop an organoid platform!

Card News. Learn more about HADD Science. @haddscience
chapter 01. 🤝 KoaSTEM ChemOn × HADD Science Agreement. The real solution to replace animal testing, organoid platforms are coming 🚀. 👇 Check out the agreement news below
chapter 02. K-startup plays its card, targeting the animal alternative testing market 🌍. Non-clinical CRO KoaSTEM ChemOn and HADD Science! On June 4, signed a joint R&D agreement to 'build a future organoid platform'.
chapter 03. Combining strengths 🤝 Safety & ADDGEL 🧫. KoaSTEM ChemOn provides cell safety-focused culture and evaluation infrastructure! HADD Science provides nucleic acid-based 3D organoid culture technology 'ADDGEL'.
chapter 04. The true significance of this agreement lies in 'market timing' 🔬. The market for New Approach Methodologies (NAMs) is rapidly opening!
chapter 04. New Approach Methodologies: Regulations are moving first. The FDA has officially adopted NAMs to replace animal testing in some Phase 1 trials, and the EU is also gradually strengthening the mandatory use of animal alternative tests.🎉. Now, evaluation models 'resembling the human body' determine the speed and cost of new drug development!
chapter 05. Brain, Heart, Liver Organoids: The Future of Drug Evaluation 💻🧬. " We are jointly envisioning the commercialization of services for new drug efficacy/toxicity evaluation and disease model evaluation by mass culturing various organoids.🧬
chapter 06. K-Bio Success Story ✨. This collaboration, which began at the GBSA Gyeonggi Bio Center Lab Station, is the first case of Korea entering the global animal alternative testing platform market as a competitor.🧬
A word from the CEO 💬. “Expand platform technology faster through open innovation”. Heo Chae-jeong, CEO of HADD Science · Song Si-hwan, CEO of KoaSTEM ChemOn
Original Article. View Original Article →. ※Clicking the page will take you to the original article.
Back to list